A drug sustained-release loading system and its preparation method and application

By mixing nucleotide drug sequences with gold nanoclusters, a drug sustained-release load system is constructed, which solves the problems of insufficient targeting and uncontrollable loading of nucleoside drugs when treating tumors, and realizes that the drug is in the tumor site efficient enrichment and improved therapeutic effect.

CN115737667BActive Publication Date: 2024-11-08RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211481177.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-24
Publication Date
2024-11-08
Estimated Expiration
2042-11-24

AI Technical Summary

Technical Problem

Existing nucleoside drugs have problems such as insufficient targeting, uncontrollable drug load, too short in vivo circulation time and batch differences in batches when treating tumors, resulting in the inability to achieve effective specificity of tumor sites.

Method used

Through solid phase synthesis method, the nucleotide drug sequence is mixed with gold nanoclusters to build a drug sustained release load system, and the drug's sustained release and targeting ability is improved by using the characteristics of gold nanoclusters.

Benefits of technology

It achieves the extension of the drug circulation time in the body, the enrichment of tumor sites and the improvement of treatment effect, while reducing the IC50 value and improving the targeting and universality of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115737667B_ABST
    Figure CN115737667B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for preparing a drug sustained-release loading system, which comprises the following steps: synthesizing a drug into a drug sequence in the form of a nucleotide chain by solid phase synthesis, and mixing the drug sequence with gold nanoclusters to obtain a drug sustained-release loading system. The drug sustained-release loading system is obtained by mixing a drug sequence in the form of a nucleotide chain with gold nanoclusters. An application of a drug sustained-release loading system, wherein the drug sustained-release loading system is used for targeted drug delivery of tumors. The method for preparing a drug sustained-release loading system of the present application utilizes the characteristics of gold nanoclusters to construct a drug sustained-release loading system, which can realize the loading and sustained release of different drugs; improve the circulation time of the drug in the body, increase the enrichment of the drug at the tumor site; reduce the IC50 value of the drug; and the drug sustained-release loading system prepared by the present application has good targeting and universality.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of drug sustained-release loading system, in particular to a drug sustained-release loading system and a preparation method and application thereof. Background Art

[0002] Nucleosides and deoxynucleosides are the basic elements of RNA and deoxyribonucleic acid. As derivatives of natural nucleosides, nucleoside drugs can block the synthesis of DNA or RNA and break the balance of natural nucleoside pools, thereby blocking viral replication or cell proliferation. Therefore, they are widely used in the treatment of viral infectious diseases, tumors, etc. Among them, 50% of antiviral drugs are nucleoside drugs, such as lamivudine for hepatitis virus, cidofovir for herpes virus, ganciclovir for cytomegalovirus, and stavudine for antiretrotranscriptase virus. Anti-tumor drugs such as 5-fluorouracil, cytarabine, and gemcitabine also belong to nucleoside drugs. Small molecule drugs such as MMAE often need to be connected with targeted molecules such as antibodies to reduce toxicity due to their high toxicity. However, antibodies have problems such as long in vivo circulation time, uncontrollable drug loading, and batch-to-batch differences. At present, no protein is expressed only in tumors, so the specificity of tumor sites cannot be fully achieved. Therefore, it is necessary to design a preparation method for a drug sustained-release loading system. Summary of the invention

[0003] In order to overcome the defects in the prior art, a method for preparing a drug sustained-release loading system is provided.

[0004] The present invention is achieved through the following scheme:

[0005] A method for preparing a drug sustained-release loading system comprises the following steps: synthesizing a drug into a drug sequence in the form of a nucleotide chain by solid phase synthesis, and mixing the drug sequence with gold nanoclusters to obtain a drug sustained-release loading system.

[0006] The drug is a nucleic acid drug.

[0007] The nucleic acid drugs include nucleic acid analogs and drugs formed by connecting with nucleic acids.

[0008] The nucleic acid drug includes a 5FU sequence, a gemcitabine sequence, and an MMAE sequence.

[0009] The sequence of the nucleic acid drug is shown in SEQ ID No: 1-3:

[0010] SEQ1:SH-5FU-5FU-5FU-5FU-5FU-5FU-SH

[0011] SEQ2:SH-Gem-Gem-Gem-Gem-SH

[0012] SEQ3: SH-TTTT-SH-MMAE

[0013] The 5FU sequence is a sequence formed by solid phase synthesis;

[0014] There is a breakable linker between the 5FU drugs; and other bases are interspersed between the 5FU drugs.

[0015] The gemcitabine sequence is a sequence formed by solid phase synthesis;

[0016] There is a breakable linker between the gemcitabine drugs; and other bases are interspersed between the gemcitabine drugs.

[0017] The MMAE drug is connected to the nucleic acid sequence, and the MMAE drug is connected through the end. The connection conditions are: Vc-MMAE and the thiol-modified DNA / RNA sequence are reacted overnight in a solution containing KCl and acetonitrile.

[0018] A drug sustained-release loading system is obtained by mixing a drug sequence in the form of a nucleotide chain with gold nanoclusters.

[0019] An application of a drug sustained-release loading system, wherein the drug sustained-release loading system is used for treating tumors.

[0020] The beneficial effects of the present invention are:

[0021] The present application discloses a method for preparing a drug sustained-release loading system, which utilizes the characteristics of gold nanoclusters to construct a drug sustained-release loading system, which can realize the loading and sustained-release of different drugs; improve the circulation time of drugs in the body, increase the enrichment of drugs in tumor sites; reduce the IC50 value of drugs; and the drug sustained-release loading system prepared by the present application has good targeting and universality. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is a schematic diagram of the construction process of the sustained-release loading system in this application;

[0023] Figure 2 Schematic diagram of clone formation experiment results;

[0024] Figure 3 Schematic diagram of the results of the in vivo targeting experiment of 5FU nanoparticles;

[0025] Figure 4 It is a schematic diagram of the therapeutic effect of 5FU nanoparticles;

[0026] Figure 5 Schematic diagram of the results of in vivo targeting of Gem nanoparticles;

[0027] Figure 6 This is a schematic diagram of the therapeutic effect of Gem nanoparticles;

[0028] Figure 7 Schematic diagram of the results of in vivo targeting of MMAE nanoparticles;

[0029] Figure 8 Schematic diagram of the therapeutic effect of MMAE nanoparticles. DETAILED DESCRIPTION

[0030] The preferred embodiments of the present invention are further described below in conjunction with the accompanying drawings:

[0031] In the present application: Gem is the abbreviation of gemcitabine, SH is the abbreviation of sulfhydryl, 5FU is the abbreviation of 5-FU drugs, GNCs is the abbreviation of gold nanoclusters, GNCs-5FU is the abbreviation of 5FU sustained-release loading system, GNCs-Gem is the abbreviation of Gem sustained-release loading system, DPBS is the abbreviation of Dulbecco's phosphate buffered saline, and GNCs-MMAE is the abbreviation of MMAE sustained-release loading system.

[0032] A method for preparing a drug sustained-release loading system comprises the following steps: synthesizing a drug into a drug sequence in the form of a nucleotide chain by solid phase synthesis, and mixing the drug sequence with gold nanoclusters to obtain a drug sustained-release loading system.

[0033] The drug is a nucleic acid drug.

[0034] The nucleic acid drugs include nucleic acid analogs and drugs formed by connecting with nucleic acids.

[0035] The nucleic acid drug includes a 5FU sequence, a gemcitabine sequence, and an MMAE sequence.

[0036] The sequence of the nucleic acid drug is shown in SEQ ID No: 1-3:

[0037] SEQ1:SH-5FU-5FU-5FU-5FU-5FU-5FU-SH

[0038] SEQ2:SH-Gem-Gem-Gem-Gem-SH

[0039] SEQ3: SH-TTTT-SH-MMAE

[0040] The 5FU sequence is a sequence formed by solid phase synthesis;

[0041] There is a breakable linker between the 5FU drugs; and other bases are interspersed between the 5FU drugs.

[0042] The gemcitabine sequence is a sequence formed by solid phase synthesis;

[0043] There is a breakable linker between the gemcitabine drugs; and other bases are interspersed between the gemcitabine drugs.

[0044] The MMAE drug is connected to the nucleic acid sequence, and the MMAE drug is connected through the end. The connection conditions are: Vc-MMAE and the thiol-modified DNA / RNA sequence are reacted overnight in a solution containing KCl and acetonitrile.

[0045] A drug sustained-release loading system is obtained by mixing a drug sequence in the form of a nucleotide chain with gold nanoclusters.

[0046] An application of a drug sustained-release loading system, wherein the drug sustained-release loading system is used for treating tumors.

[0047] The preferred embodiments of the present invention are further described below in conjunction with the embodiments:

[0048] Example 1

[0049] A method for preparing a drug sustained-release loading system comprises the following steps: synthesizing a drug into a drug sequence in the form of a nucleotide chain by solid phase synthesis, and mixing the drug sequence with gold nanoclusters to obtain a drug sustained-release loading system.

[0050] The drug sequence includes a 5-FU drug sequence.

[0051] The thiol group is located in the middle and / or at the end of the nucleotide chain.

[0052] The nucleotide sequence after thiol modification is shown in SEQ1:

[0053] SEQ1:SH-5FU-5FU-5FU-5FU-5FU-5FU-SH

[0054] The 5-FU is a 5FU nucleic acid sequence synthesized by solid phase synthesis.

[0055] A drug sustained-release loading system is obtained by mixing a drug sequence in the form of a nucleotide chain with gold nanoclusters.

[0056] An application of a drug sustained-release loading system, wherein the drug sustained-release loading system is used for targeted drug delivery to tumors.

[0057] In this example, 5FU was synthesized by solid phase synthesis and mixed with gold nanoclusters at a ratio of 1:10 to obtain 5FU-GNCs. Figure 1 shown.

[0058] 5000 colon cancer cells HCT116 were inoculated in a 6-well plate, and the drug was added after 24 hours. The medium was changed after 2 hours to remove the drug that did not enter the cells. The drug was given once every 3 days, and the experiment was terminated after 2 weeks. The cells were fixed and stained with crystal violet. The results confirmed that the toxicity of 5FU-GNCs was significantly enhanced compared with 5FU (the number of clones was reduced). Figure 2 As shown, the sustained release effect of the drug was demonstrated.

[0059] A mouse model of colon cancer was constructed, and the fluorescently modified drug (10uM, 100ul) was injected through the tail vein. The fluorescence distribution was observed by a small animal imaging instrument within 1-4 hours. The results showed that 5FU-GNCs were more enriched in the tumor site than 5FU and lasted longer. Improved in vivo targeting, such as Figure 3 shown.

[0060] In a colon cancer-bearing mouse model, the drug (10 mg / kg) was injected regularly through the tail vein, and the tumor size was measured. The results showed that 5FU-GNCs had a significantly enhanced tumor therapeutic effect compared with 5FU. Figure 4 shown.

[0061] Example 2

[0062] The same points as those in Example 1 will not be described in detail, and the differences are as follows:

[0063] The drug sequence includes a gemcitabine drug sequence.

[0064] The thiol group is located in the middle and / or at the end of the nucleotide chain.

[0065] The nucleotide sequence after thiol modification is shown in SEQ2:

[0066] SEQ2:SH-Gem-Gem-Gem-Gem-SH

[0067] The Gem is a Gem nucleic acid sequence synthesized by solid phase synthesis.

[0068] A pancreatic cancer (MIA-paca2 cell) mouse model was constructed, and the fluorescently modified drug (10uM, 100ul) was injected through the tail vein. The fluorescence distribution was observed by a small animal imager within 1-3 hours. The results showed that Gem-GNCs had better in vivo targeting than gemcitabine alone. Figure 5 shown.

[0069] In a pancreatic cancer-bearing mouse model, the drug (10 mg / kg) was injected regularly through the tail vein and the tumor size was measured. The results showed that Gem-GNCs had a significantly enhanced tumor treatment effect compared with gemcitabine. Figure 6 shown.

[0070] Example 3

[0071] The drug sequence includes an MMAE drug sequence.

[0072] The thiol group is located in the middle and / or at the end of the nucleotide chain.

[0073] The nucleotide sequence after thiol modification is shown in SEQ3:

[0074] SEQ3: SH-TTTT-SH-MMAE

[0075] The MMAE is an MMAE nucleic acid sequence synthesized by solid phase synthesis.

[0076] The conditions for connecting the MMAE drug sequence are as follows: Vc-MMAE and the thiol-modified DNA / RNA sequence are reacted overnight in a solution containing 400 mM KCl and acetonitrile.

[0077] In a lung cancer (H460 cell) tumor-bearing mouse model, the fluorescently modified drug (10uM, 100ul) was injected through the tail vein, and the fluorescence distribution was observed by a small animal imager within 1-3 hours. The results showed that MMAE-GNCs had better in vivo targeting than simple MMAE, such as Figure 7 shown.

[0078] In a lung cancer tumor-bearing mouse model, the drug (5 mg / kg) was injected regularly through the tail vein and the tumor size was measured. The results showed that MMAE-GNCs had a significantly enhanced tumor therapeutic effect compared with Vc-MMAE. Figure 8 shown.

[0079] The present application discloses a method for preparing a drug sustained-release loading system. The prepared drug sustained-release loading system can effectively improve the water solubility of the drug, extend the circulation time of the drug in the body by utilizing the large size effect of nanoparticles, increase the enrichment of the drug at the tumor site by the EPR effect of the nanoparticles, and achieve long-term sustained release of the drug at the lesion site with the help of nanoparticles.

[0080] Although the technical solutions of the present invention have been described and listed in detail, it should be understood that it is obvious to those skilled in the art to make modifications to the above embodiments or adopt equivalent alternatives. These modifications or improvements made without departing from the spirit of the present invention are within the scope of protection required by the present invention.

Claims

1. A method for preparing a drug sustained-release loading system, It is characterized in that The method comprises the following steps: synthesizing the drug into a drug sequence in the form of a nucleotide chain by solid phase synthesis, mixing the drug sequence with gold nanoclusters to obtain a drug sustained-release loading system, The drug sequence in the form of a nucleotide chain is selected from one of the following SEQ ID Nos: 1-3: 5-fluorouracil sequence SEQ1: SH-5FU-5FU-5FU-5FU-5FU-5FU-SH; Gemcitabine sequence SEQ2: SH-Gem-Gem-Gem-Gem-SH; Monomethyl auristatin E sequence SEQ3: SH-TTTT-S-MMAE.

2. A drug sustained-release loading system prepared by the method of claim 1, Features: The drug sustained-release loading system is obtained by mixing a drug sequence in the form of a nucleotide chain with gold nanoclusters.

3. An application of the drug sustained-release loading system as claimed in claim 2, Features: The drug sustained-release loading system is used for preparing drugs for treating tumors.